Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$18.51 +5.9%	$14.08	$8.04 ▼ $25.88	$474.66M	2.26	742,476 shs	505,286 shs
ARQT Arcutis Biotherapeutics	$15.98 +1.2%	$14.71	$8.03 ▼ $17.75	$1.89B	1.84	1.81 million shs	1.41 million shs
IRON Disc Medicine	$60.35 +1.0%	$56.87	$30.82 ▼ $68.73	$2.08B	0.77	332,509 shs	349,244 shs
MESO Mesoblast	$15.81 +4.2%	$13.38	$6.00 ▼ $22.00	$1.94B	2.4	151,117 shs	162,232 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	+5.89%	-4.98%	+19.81%	+51.72%	-15.40%
ARQT Arcutis Biotherapeutics	+1.20%	-5.39%	+7.18%	+14.31%	+91.61%
IRON Disc Medicine	+1.00%	+0.82%	-0.97%	+27.40%	+22.39%
MESO Mesoblast	+4.22%	-2.71%	-1.74%	+45.71%	+142.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARCT Arcturus Therapeutics	2.9609 of 5 stars	3.5	2.0	3.2	2.5	0.6
ARQT Arcutis Biotherapeutics	1.7853 of 5 stars	2.4	2.0	3.3	1.7	0.6
IRON Disc Medicine	3.5011 of 5 stars	4.5	3.0	2.6	2.5	0.0
MESO Mesoblast	2.0685 of 5 stars	2.6	4.0	2.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	3.00	Buy	$50.57	173.21% Upside
ARQT Arcutis Biotherapeutics	2.86	Moderate Buy	$19.80	23.90% Upside
IRON Disc Medicine	3.09	Buy	$98.30	62.88% Upside
MESO Mesoblast	3.20	Buy	$18.00	13.85% Upside

Current Analyst Ratings Breakdown

Latest ARCT, IRON, MESO, and ARQT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	ARCT Arcturus Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$63.00 ➝ $54.00
8/18/2025	IRON Disc Medicine	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$85.00 ➝ $90.00
8/12/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$47.00 ➝ $49.00
8/12/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $42.00
8/7/2025	ARQT Arcutis Biotherapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/7/2025	ARQT Arcutis Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
8/5/2025	MESO Mesoblast	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/25/2025	ARQT Arcutis Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$18.00
7/21/2025	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
7/21/2025	IRON Disc Medicine	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$86.00
7/18/2025	MESO Mesoblast	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$152.31M	3.30	N/A	N/A	$8.51 per share	2.18
ARQT Arcutis Biotherapeutics	$263.47M	7.27	N/A	N/A	$1.16 per share	13.78
IRON Disc Medicine	N/A	N/A	N/A	N/A	$17.67 per share	N/A
MESO Mesoblast	$5.90M	343.00	N/A	N/A	$4.21 per share	3.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$80.94M	-$2.23	N/A	N/A	N/A	-49.26%	-24.87%	-17.75%	11/6/2025 (Estimated)
ARQT Arcutis Biotherapeutics	-$140.04M	-$0.75	N/A	N/A	N/A	-35.40%	-62.62%	-25.16%	11/5/2025 (Estimated)
IRON Disc Medicine	-$109.36M	-$4.47	N/A	N/A	N/A	N/A	-26.60%	-24.58%	11/11/2025 (Estimated)
MESO Mesoblast	-$87.96M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/27/2025 (Estimated)

Latest ARCT, IRON, MESO, and ARQT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/27/2025	H2 2025	MESO Mesoblast	-$0.20	N/A	N/A	N/A	$7.48 million	N/A
8/11/2025	Q2 2025	ARCT Arcturus Therapeutics	-$1.11	-$0.34	+$0.77	-$0.34	$17.64 million	$28.30 million
8/7/2025	Q2 2025	IRON Disc Medicine	-$1.17	-$1.58	-$0.41	-$1.58	N/A	N/A
8/6/2025	Q2 2025	ARQT Arcutis Biotherapeutics	-$0.18	-$0.13	+$0.05	-$0.13	$72.70 million	$81.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	N/A	5.90	5.90
ARQT Arcutis Biotherapeutics	0.77	3.20	3.04
IRON Disc Medicine	0.05	32.11	32.11
MESO Mesoblast	0.22	0.96	0.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
ARQT Arcutis Biotherapeutics	N/A
IRON Disc Medicine	83.70%
MESO Mesoblast	1.43%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	16.60%
ARQT Arcutis Biotherapeutics	9.40%
IRON Disc Medicine	3.64%
MESO Mesoblast	18.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	27.16 million	22.65 million	Optionable
ARQT Arcutis Biotherapeutics	150	119.91 million	108.63 million	Optionable
IRON Disc Medicine	30	34.77 million	33.50 million	Not Optionable
MESO Mesoblast	80	128.00 million	103.93 million	Optionable

ARCT, IRON, MESO, and ARQT Headlines

Recent News About These Companies

Mesoblast (NASDAQ:MESO) Shares Gap Down - Should You Sell?

August 21 at 1:08 PM | marketbeat.com

Mesoblast (MESO) to Release Quarterly Earnings on Wednesday

August 21 at 2:30 AM | marketbeat.com

Mesoblast (NASDAQ:MESO) Shares Gap Up - Time to Buy?

August 16, 2025 | marketbeat.com

MESO | Mesoblast Ltd. ADR Annual Income Statement | MarketWatch

August 14, 2025 | marketwatch.com

Ulcerative Colitis Treatment Landscape Undergoes Rapid Transformation with FDA Approvals and Robust Pipeline | DelveInsight

August 13, 2025 | theglobeandmail.com

Mesoblast Limited (NASDAQ:MESO) Given Average Rating of "Buy" by Brokerages

August 9, 2025 | marketbeat.com

Mesoblast (NASDAQ:MESO) Rating Increased to Strong-Buy at Canaccord Genuity Group

August 9, 2025 | marketbeat.com

XY Capital Ltd Buys New Stake in Mesoblast Limited (NASDAQ:MESO)

August 9, 2025 | marketbeat.com

Mesoblast (NASDAQ:MESO) Shares Gap Up - Should You Buy?

July 25, 2025 | marketbeat.com

JPMorgan Acquires Substantial Stake in Mesoblast

July 23, 2025 | msn.com

Mesoblast Limited (MESO) Is Up 40.59% in One Week: What You Should Know

July 22, 2025 | zacks.com

Mesoblast shares surge on strong Ryoncil launch, tapering off after Friday rally

July 21, 2025 | proactiveinvestors.com

Why Mesoblast shares can keep storming higher

July 21, 2025 | msn.com

Mesoblast stock soars after reporting first Ryoncil sales

July 19, 2025 | investing.com

Successful Commercial Launch of Ryoncil®

July 17, 2025 | globenewswire.com

Insider Stock Buying Reaches US$205.4m On Mesoblast

July 8, 2025 | finance.yahoo.com

Mesoblast: A Cautionary Hold On Regenerative Medicine's Risky Edge (Upgrade)

July 7, 2025 | seekingalpha.com

Mesoblast Shares Surge on FDA Alignment

July 1, 2025 | sharecafe.com.auS

Mesoblast, FDA agree on marketing application for cell therapy

July 1, 2025 | msn.com

Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor

July 1, 2025 | benzinga.com

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

June 30, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ARCT, IRON, MESO, and ARQT Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$18.51 +1.03 (+5.89%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$18.16 -0.36 (-1.92%)

As of 08/22/2025 06:59 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Arcutis Biotherapeutics NASDAQ:ARQT

$15.98 +0.19 (+1.20%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$15.95 -0.03 (-0.18%)

As of 08/22/2025 07:56 PM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Disc Medicine NASDAQ:IRON

$60.35 +0.60 (+1.00%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$61.00 +0.65 (+1.08%)

As of 08/22/2025 05:45 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Mesoblast NASDAQ:MESO

$15.81 +0.64 (+4.22%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$15.78 -0.03 (-0.19%)

As of 08/22/2025 06:02 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time